Regular maintenance treatment with low-dose rituximab is associated with less disability and fewer relapses among people with neuromyelitis optica spectrum…
Articles by Patricia Inacio, PhD
Cedars-Sinai was designated a Center of Excellence in Rare Neuroimmune Disorders due to its efforts at advancing care and research…
Uplizna (inebilizumab) treatment markedly reduces the number of several subsets of immune B-cells that are linked to disease relapses…
Experiencing attacks marked by transverse myelitis, or spinal cord inflammation, significantly increases the chance of worse disability in people with…
Nearly all neuromyelitis optica spectrum disorder (NMOSD) patients who start taking Enspryng (satralizumab) are free of relapses after…
Immunosuppressive therapy significantly reduces relapses in elderly people with late-onset neuromyelitis optica spectrum disorder (NMOSD), with more than half…
Treatment with rituximab significantly reduces the risk of relapse and lessens disability in neuromyelitis optica spectrum disorder (NMOSD) patients…
The circulating levels in the blood of six inflammatory proteins may help predict the risk of relapse and severe attacks…
As many as half of people with neuromyelitis optica spectrum disorder (NMOSD) experience depression, anxiety, and/or sleep problems, according…
The clinical symptoms of neuromyelitis optica spectrum disorder (NMOSD) in people in their 50s or older may look like…